Dr. Kaminski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 E Medical Center Dr
Ann Arbor, MI 48109Phone+1 734-936-4000Fax+1 734-647-9654
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1978 - 1981
Stanford University School of MedicineClass of 1978
Certifications & Licensure
CA State Medical License 1981 - Present
MI State Medical License 1985 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma Start of enrollment: 2005 Aug 01
- Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy Start of enrollment: 2007 Apr 01
- Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma Start of enrollment: 2009 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 27 citationsNCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, Ranjana H Advani, Babis Andreadis
Journal of the National Comprehensive Cancer Network. 2023-11-01 - 5 citationsSubclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma.W Richard Burack, Hongli Li, Diana Adlowitz, Janice M Spence, Lisa M Rimsza
Blood Advances. 2023-09-12 - 5 citationsAdding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.Tycel J Phillips, David Bond, Radihka Takiar, Karson Kump, Malalthi Kandarpa
Blood Advances. 2023-08-22
Grant Support
- Iodine 131 Anti-B1 Antibody For Non-Hodgkin'S LymphomaNational Center For Research Resources2000–2002
- Retreatment Of NON Hodgkins Lymphoma W/ Iodine 131 Anti B1 AntibodyNational Center For Research Resources1999–2002
- I 131 Anti B1 Antibody In NON Hodgkins Lymphoma VS Unlabeled Anti B1National Center For Research Resources1999–2002
- (131) Iodine-B1 Radioimmunotherapy Of Advanced Nonhodgkin'S LymphomaNational Center For Research Resources1998–2002
- Radioimmunotherapy Of LymphomaNational Cancer Institute1992–2000
- Radiolabeled Monoclonal PAN B Cell Antibody In The Treatment Of B Cell LymphomasNational Center For Research Resources1996–1999
- (131) Iodine-B1 Radioimmunotherapy Of Advanced NON Hodgkin'S LymphomaNational Center For Research Resources1997
- Coulter Clone 131I B1 Radioimmunotherapy Of NON Hodgkins LymphomaNational Center For Research Resources1996
- Anti-Tumor Effects Of Anti-Idiotype AntibodiesNational Cancer Institute1990–1992
- NCI Clinical Invstigator Award ProgramNational Cancer Institute1986–1988
- Anti-Tumor Effects Of Anti-Idiotype AntibodiesNational Cancer Institute1985
Professional Memberships
- Member
Other Languages
- Polish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
